Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Nursing | Pharmacy | Surgery | Critical Care | Conference News

Back to Journal Articles

AHA: Vorapaxar Reduces Limb Ischemia in PAD

Last Updated: June 22, 2012.

 

Does not reduce risk of cardiovascular death, myocardial infarction, stroke; ups bleeding risk

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with peripheral artery disease, treatment with the platelet inhibitor vorapaxar significantly reduces the risk of hospitalization for acute limb ischemia and arterial revascularization, according to a study presented during the American Heart Association's Emerging Science Series Webinar, held on June 20.

FRIDAY, June 22 (HealthDay News) -- For patients with peripheral artery disease (PAD), treatment with the platelet inhibitor vorapaxar significantly reduces the risk of hospitalization for acute limb ischemia and arterial revascularization, according to a study presented during the American Heart Association's Emerging Science Series Webinar, held on June 20.

Marc P. Bonaca, M.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues conducted a randomized placebo-controlled trial of 2.5 mg daily vorapaxar in addition to standard care, involving 3,787 patients with PAD. Participants with a history of claudication symptoms and either an ankle brachial index of <0.85 or prior peripheral revascularization for limb ischemia were deemed eligible.

The researchers observed no significant difference in the primary end point (composite of cardiovascular death, myocardial infarction, or stroke) in patients receiving vorapaxar or placebo. For patients randomized to vorapaxar there were significantly lower rates of hospitalization for acute limb ischemia (2.3 versus 3.9 percent; P = 0.006) and peripheral arterial revascularization (18.4 versus 22.2 percent; P = 0.017). Vorapaxar was associated with a significantly increased risk of bleeding, including intracerebral hemorrhage.

"This is the first outpatient therapy that has been shown to reduce the risk of blood clots and the need for artery opening revascularization procedures in the legs in patients with PAD," Escolar said in a statement. "For clinicians and researchers, these data show the potential for therapies that can reduce leg problems in patients with PAD rather than just overall cardiovascular risk."

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which funded the study and developed vorapaxar.

Abstract
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Telehealth Intervention Linked to Lower Admission Rates Next: Increased Sick Leave Rates for Long-Term Cancer Survivors

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.